| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Access and Affordability of Medicines in Malaysia: Need for a National Pricing Policy
|
Wong, Shui Ling
|
|
2019
|
|
5 |
p. 641-654
|
artikel
|
| 2 |
A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda
|
Lubinga, Solomon J.
|
|
2015
|
|
5 |
p. 493-506
|
artikel
|
| 3 |
A Cost-Effectiveness Model for Frail Older Persons: Development and Application to a Physiotherapy-Based Intervention
|
Karnon, Jonathan
|
|
2017
|
|
5 |
p. 635-645
|
artikel
|
| 4 |
A Head-to-Head Comparison of UK SF-6D and Thai and UK EQ-5D-5L Value Sets in Thai Patients with Chronic Diseases
|
Sakthong, Phantipa
|
|
2017
|
|
5 |
p. 669-679
|
artikel
|
| 5 |
Alcohol Reform in Viet Nam
|
Tam, Nguyen Minh
|
|
2012
|
|
5 |
p. 285-287
|
artikel
|
| 6 |
Alcohol Reform in Viet Nam
|
Tam, Nguyen Minh
|
|
2012
|
|
5 |
p. 285-287
|
artikel
|
| 7 |
Allocating Public Spending Efficiently: Is There a Need for a Better Mechanism to Inform Decisions in the UK and Elsewhere?
|
Cubi-Molla, Patricia
|
|
|
|
5 |
p. 635-644
|
artikel
|
| 8 |
An Economic Evaluation of Government-Funded COVID-19 Testing in Australia
|
Karnon, Jonathan
|
|
|
|
5 |
p. 681-691
|
artikel
|
| 9 |
An Interrupted Time-Series Analysis to Assess Impact of Introduction of Co-Payment on Emergency Room Visits in Cyprus
|
Petrou, Panagiotis
|
|
2015
|
|
5 |
p. 515-523
|
artikel
|
| 10 |
A Probe into the Wages and Salaries of Health Economics, Outcomes Research, and Market Access Professionals
|
Carvajal, Manuel J.
|
|
2019
|
|
5 |
p. 741-751
|
artikel
|
| 11 |
A Qualitative Evaluation of Program Budgeting and Marginal Analysis in a Canadian Pediatric Tertiary Care Institution
|
Smith, Neale
|
|
2016
|
|
5 |
p. 559-568
|
artikel
|
| 12 |
A Review of Web-Based Tools for Value-of-Information Analysis
|
Tuffaha, Haitham
|
|
|
|
5 |
p. 645-651
|
artikel
|
| 13 |
Assessing quality of life among British older people using the ICEPOP CAPability (ICECAP-O) measure
|
Flynn, Terry N.
|
|
2011
|
|
5 |
p. 317-329
|
artikel
|
| 14 |
A Systematic Review and Narrative Synthesis of Health Economic Studies Conducted for Hereditary Haemochromatosis
|
Graaff, Barbara de
|
|
2015
|
|
5 |
p. 469-483
|
artikel
|
| 15 |
A Systematic Review of Cost-Effectiveness Analyses of Colorectal Cancer Screening in Europe: Have Studies Included Optimal Screening Intensities?
|
Pokharel, Rajani
|
|
|
|
5 |
p. 701-717
|
artikel
|
| 16 |
A Systematic Review of Economic Evaluations of the Use of Robotic Assisted Laparoscopy in Surgery Compared with Open or Laparoscopic Surgery
|
Tandogdu, Zafer
|
|
2015
|
|
5 |
p. 457-467
|
artikel
|
| 17 |
A Systematic Review of Productivity in Economic Evaluations of Workplace Interventions: A Need for Reporting Criteria?
|
Jones, Cheryl
|
|
2019
|
|
5 |
p. 591-613
|
artikel
|
| 18 |
A Systematic Review of the Association Between Hospital Cost/price and the Quality of Care
|
Jamalabadi, Sara
|
|
|
|
5 |
p. 625-639
|
artikel
|
| 19 |
A Systematic Review of the Costs Relating to Non-pharmaceutical Interventions Against Infectious Disease Outbreaks
|
Skarp, Janetta E.
|
|
|
|
5 |
p. 673-697
|
artikel
|
| 20 |
Authors’ Reply to Curto and Garattini: “Current Status and Trends in Performance-Based Risk-Sharing Arrangements Between Healthcare Payers and Medical Product Manufacturers”
|
Carlson, Josh J.
|
|
2014
|
|
5 |
p. 567-568
|
artikel
|
| 21 |
Authors’ Reply to Dr. Malerbi: “Insulin Glargine in a Brazilian State: Should the Government Disinvest?”
|
Souza, Ana Luísa Caires de
|
|
2014
|
|
5 |
p. 561-563
|
artikel
|
| 22 |
Authors’ Reply to Liedgens and Henske: “Cost-Utility Analysis of Duloxetine in Osteoarthritis: A US Private Payer Perspective”
|
Wielage, Ronald C.
|
|
2013
|
|
5 |
p. 555-557
|
artikel
|
| 23 |
Barrier to Access or Cost Share? Coinsurance and Dental-Care Utilization in Colombia
|
Higuera, Lucas
|
|
2016
|
|
5 |
p. 569-578
|
artikel
|
| 24 |
Budget Impact Analysis of Molecular Lymph Node Staging Versus Conventional Histopathology Staging in Colorectal Carcinoma
|
Diaz-Mercedes, Sherley
|
|
2019
|
|
5 |
p. 655-667
|
artikel
|
| 25 |
Budget Impact Analysis of the Introduction of Subcutaneous Infliximab (CT-P13 SC) for the Treatment of Rheumatoid Arthritis in the United Kingdom
|
Byun, Han Geul
|
|
|
|
5 |
p. 735-745
|
artikel
|
| 26 |
Burden and cost of hospital admissions for vaccine-preventable paediatric pneumococcal disease and non-typable Haemophilus influenzae otitis media in New Zealand
|
Milne, Richard J.
|
|
2010
|
|
5 |
p. 281-300
|
artikel
|
| 27 |
Care Appropriateness and Health Productivity Evolution: A Non-Parametric Analysis of the Italian Regional Health Systems
|
Mancuso, Paolo
|
|
2016
|
|
5 |
p. 595-607
|
artikel
|
| 28 |
Centralised Pharmaceutical Procurement: Learnings from Six European Countries
|
Vogler, Sabine
|
|
|
|
5 |
p. 637-650
|
artikel
|
| 29 |
Clinical Governance in Italy: ‘Made in England’ for Import?
|
Garattini, Livio
|
|
2017
|
|
5 |
p. 541-544
|
artikel
|
| 30 |
Clopidogrel versus Aspirin in Patients with Atherothrombosis
|
Kourlaba, Georgia
|
|
2012
|
|
5 |
p. 331-342
|
artikel
|
| 31 |
Clopidogrel versus Aspirin in Patients with Atherothrombosis
|
Kourlaba, Georgia
|
|
2012
|
|
5 |
p. 331-342
|
artikel
|
| 32 |
Comment on: “Cost-Utility Analysis of Duloxetine in Osteoarthritis: A US Private Payer Perspective”
|
Liedgens, Hiltrud
|
|
2013
|
|
5 |
p. 553-554
|
artikel
|
| 33 |
Comment on: “Current Status and Trends in Performance-Based Risk-Sharing Arrangements Between Healthcare Payers and Medical Product Manufacturers”
|
Curto, Alessandro
|
|
2014
|
|
5 |
p. 565
|
artikel
|
| 34 |
Comment on: “Disease-Specific Out-of-Pocket Payments, Catastrophic Health Expenditure and Impoverishment Effects in India: An Analysis of National Health Survey Data”
|
Faizi, Nafis
|
|
|
|
5 |
p. 783-784
|
artikel
|
| 35 |
Comment on: “Insulin Glargine in a Brazilian State: Should the Government Disinvest?”
|
Malerbi, Domingos A.
|
|
2014
|
|
5 |
p. 559-560
|
artikel
|
| 36 |
Comment on: “The Italian NHS: What Lessons to Draw from COVID-19?”
|
Golinelli, Davide
|
|
|
|
5 |
p. 739-741
|
artikel
|
| 37 |
Comparing Hospital-Based Resource Utilization and Costs for Prostate Cancer Patients With and Without Bone Metastases
|
Seal, Brian
|
|
2014
|
|
5 |
p. 547-557
|
artikel
|
| 38 |
Consumers' Preferences and Willingness to Pay for Personalised Nutrition
|
Pérez-Troncoso, Daniel
|
|
|
|
5 |
p. 757-767
|
artikel
|
| 39 |
Correction to: Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations
|
Husereau, Don
|
|
|
|
5 |
p. 781-782
|
artikel
|
| 40 |
Correction to: The False Economy of Seeking to Eliminate Delayed Transfers of Care: Some Lessons from Queueing Theory
|
Wood, Richard M.
|
|
|
|
5 |
p. 821
|
artikel
|
| 41 |
Cost-Effectiveness Analysis of Early Treatment of Chronic HCV with Sofosbuvir/Velpatasvir in Italy
|
Ruggeri, Matteo
|
|
2018
|
|
5 |
p. 711-722
|
artikel
|
| 42 |
Cost-Effectiveness Analysis of Supervised Exercise Training in Men with Prostate Cancer Previously Treated with Radiation Therapy and Androgen-Deprivation Therapy
|
Edmunds, Kim
|
|
|
|
5 |
p. 727-737
|
artikel
|
| 43 |
Cost-Effectiveness and Budget Impact Analysis of Implementing a 'Soft Opt-Out' System for Kidney Donation in Australia
|
Senanayake, Sameera
|
|
|
|
5 |
p. 769-779
|
artikel
|
| 44 |
Cost-Effectiveness of Anti-retroviral Adherence Interventions for People Living with HIV: A Systematic Review of Decision Analytical Models
|
Ahmed, Ali
|
|
|
|
5 |
p. 731-750
|
artikel
|
| 45 |
Cost-Effectiveness of a Psycho-Educational Intervention Targeting Fear of Cancer Recurrence in People Treated for Early-Stage Melanoma
|
Dieng, Mbathio
|
|
2019
|
|
5 |
p. 669-681
|
artikel
|
| 46 |
Cost effectiveness of chemoprevention for prostate cancer with dutasteride in a high-risk population based on results from the REDUCE Clinical trial
|
Kattan, Michael W.
|
|
2011
|
|
5 |
p. 305-315
|
artikel
|
| 47 |
Cost Effectiveness of Denosumab versus Oral Bisphosphonates for Postmenopausal Osteoporosis in the US
|
Parthan, Anju
|
|
2013
|
|
5 |
p. 485-497
|
artikel
|
| 48 |
Cost Effectiveness of Genotype-Guided Warfarin Dosing in Patients with Mechanical Heart Valve Replacement Under the Fee-for-Service System
|
Kim, Dong-Jin
|
|
2017
|
|
5 |
p. 657-667
|
artikel
|
| 49 |
Cost effectiveness of long-acting risperidone in Sweden
|
Hensen, Marja
|
|
2010
|
|
5 |
p. 327-341
|
artikel
|
| 50 |
Cost Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany
|
Zeidler, Jan
|
|
2013
|
|
5 |
p. 509-521
|
artikel
|
| 51 |
Cost Effectiveness of Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in Ireland
|
Lee, Dawn
|
|
2013
|
|
5 |
p. 457-469
|
artikel
|
| 52 |
Cost-Effectiveness of School-Based Prevention of Cannabis Use
|
Deogan, Charlotte
|
|
2015
|
|
5 |
p. 525-542
|
artikel
|
| 53 |
Cost-Effectiveness of Subsequent Whole-Brain Radiotherapy or Hippocampal-Avoidant Whole-Brain Radiotherapy Versus Stereotactic Radiosurgery or Surgery Alone for Treatment of Melanoma Brain Metastases
|
Tran, Anh Dam
|
|
|
|
5 |
p. 679-687
|
artikel
|
| 54 |
Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstructive Pulmonary Disease: Analyses Conducted for Canada, France, Italy, and Portugal
|
Reza Maleki-Yazdi, M.
|
|
2016
|
|
5 |
p. 579-594
|
artikel
|
| 55 |
Cost of illness and drivers of cost in atrial fibrillation in Sweden and Germany
|
Jönsson, Linus
|
|
2010
|
|
5 |
p. 317-325
|
artikel
|
| 56 |
Cost of Purchased Versus Produced Plasma from Donor Recruitment Through Transfusion
|
Prioli, Katherine M.
|
|
2016
|
|
5 |
p. 609-617
|
artikel
|
| 57 |
Cost of Trauma Care in Secondary- and Tertiary-Care Public Sector Hospitals in North India
|
Sangwan, Ankur
|
|
2017
|
|
5 |
p. 681-692
|
artikel
|
| 58 |
Costs in the Treatment of Schizophrenia in Adults Receiving Atypical Antipsychotics: An 11-Year Cohort in Brazil
|
Barbosa, Wallace Breno
|
|
2018
|
|
5 |
p. 697-709
|
artikel
|
| 59 |
Developing a Framework for the Health Technology Assessment of Histology-independent Precision Oncology Therapies
|
Gaultney, Jennifer G.
|
|
|
|
5 |
p. 625-634
|
artikel
|
| 60 |
Developing Attributes and Attribute-Levels for a Discrete-Choice Experiment: An Example for Interventions of Impulsive Violent Offenders
|
Settumba, Stella Nalukwago
|
|
2019
|
|
5 |
p. 683-705
|
artikel
|
| 61 |
Development of Conversion Functions Mapping the FACT-B Total Score to the EQ-5D-5L Utility Value by Three Linking Methods and Comparison with the Ordinary Least Square Method
|
Lee, Chun Fan
|
|
2018
|
|
5 |
p. 685-695
|
artikel
|
| 62 |
Diagnostic Needle Arthroscopy and the Economics of Improved Diagnostic Accuracy: A Cost Analysis
|
Voigt, Jeffrey D.
|
|
2014
|
|
5 |
p. 523-535
|
artikel
|
| 63 |
Disease-Specific Out-of-Pocket Payments, Catastrophic Health Expenditure and Impoverishment Effects in India: An Analysis of National Health Survey Data
|
Yadav, Jeetendra
|
|
|
|
5 |
p. 769-782
|
artikel
|
| 64 |
Does the Choice of Health Metric, DALY or QALY, Influence Conclusions of Health Economic Evaluation? A Case Study of Rotavirus Vaccine in Burundi
|
Niyibitegeka, Fulgence
|
|
|
|
5 |
p. 707-716
|
artikel
|
| 65 |
Does the Type of Provider and the Place of Residence Matter in the Utilization of Prenatal Ultrasonography? Evidence from Canada
|
Guliani, Harminder
|
|
2013
|
|
5 |
p. 471-484
|
artikel
|
| 66 |
Early assessment of medical technologies to inform product development and market access
|
Ijzerman, Maarten J.
|
|
2011
|
|
5 |
p. 331-347
|
artikel
|
| 67 |
Economic efficiency of alcohol policy
|
Doran, Christopher M.
|
|
2010
|
|
5 |
p. 351-354
|
artikel
|
| 68 |
Economic Evaluation of a Tumour-Agnostic Therapy: Dutch Economic Value of Larotrectinib in TRK Fusion-Positive Cancers
|
Michels, Renée E.
|
|
|
|
5 |
p. 717-729
|
artikel
|
| 69 |
Economic Evaluation of Cardio inCode®, a Clinical-Genetic Function for Coronary Heart Disease Risk Assessment
|
Ramírez de Arellano, A.
|
|
2013
|
|
5 |
p. 531-542
|
artikel
|
| 70 |
Economic Evaluation of Triple Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate for the Treatment of Moderate to Very Severe Chronic Obstructive Pulmonary Disease in China Using a Semi-Markov Model
|
Liu, Jia
|
|
|
|
5 |
p. 743-755
|
artikel
|
| 71 |
Economic Evaluations of Guideline-Based Care for Chronic Wounds: a Systematic Review
|
Cheng, Qinglu
|
|
2018
|
|
5 |
p. 633-651
|
artikel
|
| 72 |
Economic Evaluations of Thrombophilia Screening Prior to Prescribing Combined Oral Contraceptives: A Systematic and Critical Review
|
Vernon, Erin
|
|
2017
|
|
5 |
p. 583-595
|
artikel
|
| 73 |
Effects of Monetary Incentives in Physician Groups: A Systematic Review of Reviews
|
Heider, Ann-Kathrin
|
|
|
|
5 |
p. 655-667
|
artikel
|
| 74 |
ENTIMOS: A Discrete Event Simulation Model for Maximising Efficiency of Infusion Suites in Centres Treating Multiple Sclerosis Patients
|
Lacinova, Kristyna
|
|
|
|
5 |
p. 731-742
|
artikel
|
| 75 |
Erratum to: Cost effectiveness of secondary vs tertiary prevention for post-menopausal osteoporosis
|
Mueller, D.
|
|
2011
|
|
5 |
p. 348
|
artikel
|
| 76 |
Estimating Incremental Costs with Skew
|
Polgreen, Linnea A.
|
|
2012
|
|
5 |
p. 319-329
|
artikel
|
| 77 |
Estimating Incremental Costs with Skew
|
Polgreen, Linnea A.
|
|
2012
|
|
5 |
p. 319-329
|
artikel
|
| 78 |
Estimating the Unit Costs of Healthcare Service Delivery in India: Addressing Information Gaps for Price Setting and Health Technology Assessment
|
Bahuguna, Pankaj
|
|
|
|
5 |
p. 699-711
|
artikel
|
| 79 |
Ethical Objections Against Including Life-Extension Costs in Cost-Effectiveness Analysis: A Consistent Approach
|
Gandjour, Afschin
|
|
2014
|
|
5 |
p. 471-476
|
artikel
|
| 80 |
E-Vita Open Plus for Treating Complex Aneurysms and Dissections of the Thoracic Aorta: A NICE Medical Technology Guidance
|
Radhakrishnan, Muralikrishnan
|
|
2014
|
|
5 |
p. 485-495
|
artikel
|
| 81 |
Evolutions in Both Co-Payment and Generic Market Share for Common Medication in the Belgian Reference Pricing System
|
Fraeyman, Jessica
|
|
2013
|
|
5 |
p. 543-552
|
artikel
|
| 82 |
Examining the Influence of Antenatal Care Visits and Skilled Delivery on Neonatal Deaths in Ghana
|
Lambon-Quayefio, Monica P.
|
|
2014
|
|
5 |
p. 511-522
|
artikel
|
| 83 |
Excess costs associated with patients with pulmonary arterial hypertension in a US privately insured population
|
Kirson, Noam Y.
|
|
2011
|
|
5 |
p. 293-303
|
artikel
|
| 84 |
EXOGEN Ultrasound Bone Healing System for Long Bone Fractures with Non-Union or Delayed Healing: A NICE Medical Technology Guidance
|
Higgins, Ailish
|
|
2014
|
|
5 |
p. 477-484
|
artikel
|
| 85 |
Factors Influencing the Cost-Effectiveness Outcomes of HPV Vaccination and Screening Interventions in Low-to-Middle-Income Countries (LMICs): A Systematic Review
|
Okeah, Bernard O.
|
|
|
|
5 |
p. 641-654
|
artikel
|
| 86 |
Five-Year Evolution of Drug Prescribing in a University Adult Intensive Care Unit
|
Carron, Christine
|
|
2012
|
|
5 |
p. 355-358
|
artikel
|
| 87 |
Five-Year Evolution of Drug Prescribing in a University Adult Intensive Care Unit
|
Carron, Christine
|
|
2012
|
|
5 |
p. 355-358
|
artikel
|
| 88 |
General Trends in Prices and Prescription Patterns of Anticonvulsants in Germany between 2000 and 2017: Analysis of National and Cohort-Based Data
|
Willems, Laurent M.
|
|
2019
|
|
5 |
p. 707-722
|
artikel
|
| 89 |
Generic Medicines: Solutions for a Sustainable Drug Market?
|
Dylst, Pieter
|
|
2013
|
|
5 |
p. 437-443
|
artikel
|
| 90 |
Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007
|
Orofino, Javier
|
|
2010
|
|
5 |
p. 301-315
|
artikel
|
| 91 |
Gun Policy in the United States: Evidence-Based Strategies to Reduce Gun Violence
|
Crifasi, Cassandra
|
|
2018
|
|
5 |
p. 579-581
|
artikel
|
| 92 |
Health Economic Evaluations of Sofosbuvir for Treatment of Chronic Hepatitis C: a Systematic Review
|
Luhnen, Miriam
|
|
2016
|
|
5 |
p. 527-543
|
artikel
|
| 93 |
Health Promoting Schools: An Update
|
Lee, Albert
|
|
|
|
5 |
p. 605-623
|
artikel
|
| 94 |
Health Reform in Aotearoa New Zealand: Insights on Health Equity Challenges One Year On
|
Lorgelly, Paula K.
|
|
|
|
5 |
p. 683-687
|
artikel
|
| 95 |
Health Technology Assessment as Part of a Broader Process for Priority Setting and Resource Allocation
|
Mitton, Craig
|
|
2019
|
|
5 |
p. 573-576
|
artikel
|
| 96 |
How Much Money Should be Paid for a Patient to Isolate During the COVID-19 Outbreak? A Discrete Choice Experiment in Iran
|
Homaie Rad, Enayatollah
|
|
|
|
5 |
p. 709-719
|
artikel
|
| 97 |
Impact of Reducing Glycated Hemoglobin on Healthcare Costs Among a Population with Uncontrolled Diabetes
|
Bansal, Megha
|
|
2018
|
|
5 |
p. 675-684
|
artikel
|
| 98 |
Implementing Guidelines: The Cost and Clinical Impact of Anticoagulants in the UK Atrial Fibrillation Population
|
Shields, Gemma E.
|
|
2015
|
|
5 |
p. 543-551
|
artikel
|
| 99 |
Implementing Lifestyle Change Interventions to Prevent Type 2 Diabetes in US Medicaid Programs: Cost Effectiveness, and Cost, Health, and Health Equity Impact
|
Laxy, Michael
|
|
|
|
5 |
p. 713-726
|
artikel
|
| 100 |
Including Pharmaceuticals in Bundled Payments
|
Anderson, Gerard F.
|
|
|
|
5 |
p. 625-628
|
artikel
|
| 101 |
Incorporating Process Utility into Cost-Effectiveness Analysis via a Bolt-On Domain to the SF-6D: An Exploratory Study
|
Brennan, Victoria K.
|
|
|
|
5 |
p. 747-756
|
artikel
|
| 102 |
Information Asymmetry in Hospitals: Evidence of the Lack of Cost Awareness in Clinicians
|
Fabes, Jeremy
|
|
|
|
5 |
p. 693-706
|
artikel
|
| 103 |
Integrating Qualitative Techniques in Model Development: A Case Study Using the Framework Approach
|
Frempong, Samuel N.
|
|
2018
|
|
5 |
p. 723-733
|
artikel
|
| 104 |
Is Compulsory Licensing Bad for Public Health? Some Critical Comments on Drug Accessibility in Developing Countries
|
Guennif, Samira
|
|
2017
|
|
5 |
p. 557-565
|
artikel
|
| 105 |
Is More Expensive Medical Technology Better?
|
Voigt, Jeffrey
|
|
2012
|
|
5 |
p. 289-293
|
artikel
|
| 106 |
Is More Expensive Medical Technology Better?
|
Voigt, Jeffrey
|
|
2012
|
|
5 |
p. 289-293
|
artikel
|
| 107 |
Issues surrounding orphan disease and orphan drug policies in Europe
|
Denis, Alain
|
|
2010
|
|
5 |
p. 343-350
|
artikel
|
| 108 |
Lifetime Productivity Losses Associated with Obesity Status in Early Adulthood
|
Neovius, Kristian
|
|
2012
|
|
5 |
p. 309-317
|
artikel
|
| 109 |
Lifetime Productivity Losses Associated with Obesity Status in Early Adulthood
|
Neovius, Kristian
|
|
2012
|
|
5 |
p. 309-317
|
artikel
|
| 110 |
Limiting Free Pricing of New Innovative Drugs After Launch: A Necessity for Payers?
|
Gandjour, Afschin
|
|
2016
|
|
5 |
p. 507-509
|
artikel
|
| 111 |
Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16)
|
Pollock, Richard F.
|
|
2019
|
|
5 |
p. 615-627
|
artikel
|
| 112 |
Medicare’s Mission to Change How Health Care is Paid for and Delivered: A Cloud with a Silver Lining or Just a Dark Cloud?
|
Voigt, Jeffrey
|
|
2015
|
|
5 |
p. 433-435
|
artikel
|
| 113 |
Modeling Medicaid and Medicare Savings from Reduced Poverty and Disability to Promote Investment in Mental Health and Substance Use Interventions in the USA
|
Counts, Nathaniel Z.
|
|
|
|
5 |
p. 601-604
|
artikel
|
| 114 |
myCOPD App for Managing Chronic Obstructive Pulmonary Disease: A NICE Medical Technology Guidance for a Digital Health Technology
|
Davies, Heather
|
|
|
|
5 |
p. 689-700
|
artikel
|
| 115 |
NICE Medical Technologies Guidance
|
Campbell, Bruce
|
|
2012
|
|
5 |
p. 295-297
|
artikel
|
| 116 |
NICE Medical Technologies Guidance
|
Campbell, Bruce
|
|
2012
|
|
5 |
p. 295-297
|
artikel
|
| 117 |
Nutrition therapy cost analysis in the US
|
Turpin, Robin S.
|
|
2011
|
|
5 |
p. 281-292
|
artikel
|
| 118 |
Opportunities for Use of Blockchain Technology in Medicine
|
Radanović, Igor
|
|
2018
|
|
5 |
p. 583-590
|
artikel
|
| 119 |
Out-of-Pocket Payments and Subjective Unmet Need of Healthcare
|
Schokkaert, Erik
|
|
2017
|
|
5 |
p. 545-555
|
artikel
|
| 120 |
Paucity and Inconsistency: A Systematic Review and Critique of Budget Impact Analyses of Disease-Modifying Therapies for Multiple Sclerosis in the UK and the Implications for Policy in the UK
|
Montgomery, Stephen
|
|
2016
|
|
5 |
p. 545-558
|
artikel
|
| 121 |
PleurX Peritoneal Catheter Drainage System for Vacuum-Assisted Drainage of Treatment-Resistant, Recurrent Malignant Ascites
|
White, Judith
|
|
2012
|
|
5 |
p. 299-308
|
artikel
|
| 122 |
PleurX Peritoneal Catheter Drainage System for Vacuum-Assisted Drainage of Treatment-Resistant, Recurrent Malignant Ascites
|
White, Judith
|
|
2012
|
|
5 |
p. 299-308
|
artikel
|
| 123 |
Predicting Productivity Losses from Health-Related Quality of Life Using Patient Data
|
Mukuria, Clara
|
|
2017
|
|
5 |
p. 597-614
|
artikel
|
| 124 |
Preferences for Colorectal Cancer Screening Techniques and Intention to Attend: a Multi-Criteria Decision Analysis
|
Hummel, J. Marjan
|
|
2013
|
|
5 |
p. 499-507
|
artikel
|
| 125 |
Preferences for Enhanced Primary Care Services Among Older Individuals and Primary Care Physicians
|
Ozdemir, Semra
|
|
|
|
5 |
p. 785-797
|
artikel
|
| 126 |
Preferences for Weight Loss Treatment Amongst Treatment-Seeking Patients with Severe Obesity: A Discrete Choice Experiment
|
Queally, Michelle
|
|
|
|
5 |
p. 689-698
|
artikel
|
| 127 |
Preferred Reporting Items for Studies Mapping onto Preference-Based Outcome Measures: The MAPS Statement
|
Petrou, Stavros
|
|
2015
|
|
5 |
p. 437-443
|
artikel
|
| 128 |
Private Expenditures on Brand Name Prescription Drugs after Generic Entry
|
Balaban, Dahlia Y.
|
|
2013
|
|
5 |
p. 523-529
|
artikel
|
| 129 |
Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults
|
McGirr, Ashleigh
|
|
2019
|
|
5 |
p. 723-732
|
artikel
|
| 130 |
Role of Cost on Failure to Access Prescribed Pharmaceuticals: The Case of Statins
|
McRae, Ian
|
|
2017
|
|
5 |
p. 625-634
|
artikel
|
| 131 |
Shaping Pharmaceutical Tenders for Effectiveness and Sustainability in Countries with Expanding Healthcare Coverage
|
Maniadakis, Nikolaos
|
|
2018
|
|
5 |
p. 591-607
|
artikel
|
| 132 |
Stated Uptake of Physical Activity Rewards Programmes Among Active and Insufficiently Active Full-Time Employees
|
Ozdemir, Semra
|
|
2017
|
|
5 |
p. 647-656
|
artikel
|
| 133 |
Striving for a Societal Perspective: A Framework for Economic Evaluations When Costs and Effects Fall on Multiple Sectors and Decision Makers
|
Walker, Simon
|
|
2019
|
|
5 |
p. 577-590
|
artikel
|
| 134 |
Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy
|
Sampson, Chris
|
|
|
|
5 |
p. 651-667
|
artikel
|
| 135 |
Supporting Medicare Health, Equity and Efficiency in Australia: Policies Undermining Bulk Billing Need to Be Scrapped
|
Eckermann, Simon
|
|
2016
|
|
5 |
p. 511-514
|
artikel
|
| 136 |
Symptomatic SARS-CoV-2 Episodes and Health-Related Quality of Life
|
Alacevich, Caterina
|
|
|
|
5 |
p. 761-771
|
artikel
|
| 137 |
Systematic Review of Drug Administration Costs and Implications for Biopharmaceutical Manufacturing
|
Tetteh, Ebenezer
|
|
2013
|
|
5 |
p. 445-456
|
artikel
|
| 138 |
The Choice of Transcatheter Aortic Valve Implementation (TAVI): Do Patient Co-morbidity and Hospital Ownership Type Matter?
|
Schneider, Udo
|
|
2018
|
|
5 |
p. 735-744
|
artikel
|
| 139 |
The Economic Burden of Abuse of Prescription Opioids: A Systematic Literature Review from 2012 to 2017
|
Reinhart, Marcia
|
|
2018
|
|
5 |
p. 609-632
|
artikel
|
| 140 |
The Economic Burden of Asthma in Greece: A Cross-Sectional Study
|
Vellopoulou, Katerina
|
|
2019
|
|
5 |
p. 629-640
|
artikel
|
| 141 |
The Economic Cost of Rising Non-communicable Diseases in India: A Systematic Literature Review of Methods and Estimates
|
Shukla, Varsha
|
|
|
|
5 |
p. 719-730
|
artikel
|
| 142 |
The Impact of Financing Health Services on Income Inequality in an Unequal Society: The Case of South Africa
|
Ataguba, John E.
|
|
|
|
5 |
p. 721-733
|
artikel
|
| 143 |
The Impact of Patent Expiry on Drug Prices: A Systematic Literature Review
|
Vondeling, Gerard T.
|
|
2018
|
|
5 |
p. 653-660
|
artikel
|
| 144 |
The Impact on Health Outcomes and Healthcare Utilisation of Switching to Generic Medicines Consequent to Reference Pricing: The Case of Lamotrigine in New Zealand
|
Lessing, Charon
|
|
2014
|
|
5 |
p. 537-546
|
artikel
|
| 145 |
The Inclusion of Comparative Environmental Impact in Health Technology Assessment: Practical Barriers and Unintended Consequences
|
Pekarsky, Brita A. K.
|
|
|
|
5 |
p. 597-599
|
artikel
|
| 146 |
The PLASMA System for Transurethral Resection of the Prostate: A NICE Medical Technologies Guidance Update
|
Knight, Laura
|
|
|
|
5 |
p. 665-672
|
artikel
|
| 147 |
The Potential Benefits of Deferred Payment for a Hypothetical Gene Therapy for Congestive Heart Failure: A Cost-Consequence Analysis
|
Hlávka, Jakub P.
|
|
|
|
5 |
p. 669-677
|
artikel
|
| 148 |
The Real-World Cost-Effectiveness of Coronary Artery Bypass Surgery Versus Stenting in High-Risk Patients: Propensity Score-Matched Analysis of a Single-Centre Experience
|
Ariyaratne, Thathya V.
|
|
2018
|
|
5 |
p. 661-674
|
artikel
|
| 149 |
The Robustness and Effectiveness of the Triage System at Times of Overcrowding and the Extra Costs due to Inappropriate Use of Emergency Departments
|
Cremonesi, Paolo
|
|
2015
|
|
5 |
p. 507-514
|
artikel
|
| 150 |
The Urolift System for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A NICE Medical Technology Guidance
|
Ray, Alistair
|
|
2016
|
|
5 |
p. 515-526
|
artikel
|
| 151 |
The XprESS Multi-Sinus Dilation System for the Treatment of Chronic Sinusitis: A NICE Medical Technology Guidance
|
Jenks, Michelle
|
|
2017
|
|
5 |
p. 567-582
|
artikel
|
| 152 |
Treatment Patterns, Overall Survival, and Total Healthcare Costs of Advanced Merkel Cell Carcinoma in the USA
|
Steuten, Lotte
|
|
2019
|
|
5 |
p. 733-740
|
artikel
|
| 153 |
UroLift for Treating Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A NICE Medical Technology Guidance Update
|
Knight, Laura
|
|
|
|
5 |
p. 669-680
|
artikel
|
| 154 |
User Fees in General Practice: Willingness to Pay and Potential Substitution Patterns—Results from a Danish GP Patient Survey
|
Kronborg, Christian
|
|
2017
|
|
5 |
p. 615-624
|
artikel
|
| 155 |
Using Constrained Optimization for the Allocation of COVID-19 Vaccines in the Philippines
|
Buhat, Christian Alvin H.
|
|
|
|
5 |
p. 699-708
|
artikel
|
| 156 |
Using Economics to Impact Local Obesity Policy: Introducing the UK Centre for Economics of Obesity (CEO)
|
Frew, Emma
|
|
|
|
5 |
p. 629-635
|
artikel
|
| 157 |
Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland
|
Michaeli, Daniel Tobias
|
|
|
|
5 |
p. 757-768
|
artikel
|
| 158 |
Value for Money of CAR-T Cell Therapy for Patients with Diffuse Large B-cell Lymphoma in China: Evidence from a Cost-Effectiveness Analysis
|
Wu, Weijia
|
|
|
|
5 |
p. 773-783
|
artikel
|
| 159 |
Values in Modelling: Video Series Development and Evaluation Survey
|
Harvard, Stephanie
|
|
|
|
5 |
p. 813-820
|
artikel
|
| 160 |
Valuing Child Health Utility 9D Health States with Young Adults: Insights from a Time Trade Off Study
|
Ratcliffe, Julie
|
|
2015
|
|
5 |
p. 485-492
|
artikel
|
| 161 |
Vision Amniotic Leak Detector (ALD) to Eliminate Amniotic Fluid Leakage as a Cause of Vaginal Wetness in Pregnancy: A NICE Medical Technology Guidance
|
Ray, A. F.
|
|
2015
|
|
5 |
p. 445-456
|
artikel
|
| 162 |
What About Offering a Financial Incentive Directly to Clinical Units to Encourage the Use of Biosimilars? Results of a Two-Year National Experiment in France
|
Tano, Marion
|
|
|
|
5 |
p. 799-811
|
artikel
|
| 163 |
What is the Quality of Economic Evaluations of Non-Drug Therapies? A Systematic Review and Critical Appraisal of Economic Evaluations of Radiotherapy for Cancer
|
Barbieri, M.
|
|
2014
|
|
5 |
p. 497-510
|
artikel
|
| 164 |
‘What You See is All There is’: The Importance of Heuristics in Cost-Benefit Analysis (CBA) and Social Return on Investment (SROI) in the Evaluation of Public Health Interventions
|
Edwards, Rhiannon Tudor
|
|
|
|
5 |
p. 653-664
|
artikel
|
| 165 |
Work Productivity and Healthcare Resource Utilization Outcomes for Patients on Etanercept for Moderate-to-Severe Plaque Psoriasis
|
Vender, Ronald
|
|
2012
|
|
5 |
p. 343-353
|
artikel
|
| 166 |
Work Productivity and Healthcare Resource Utilization Outcomes for Patients on Etanercept for Moderate-to-Severe Plaque Psoriasis
|
Vender, Ronald
|
|
2012
|
|
5 |
p. 343-353
|
artikel
|
| 167 |
10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?
|
Büssgen, Melanie
|
|
|
|
5 |
p. 751-759
|
artikel
|
Tijdschrift beschrijving